Doximity Receives 'Moderate Buy' Rating from Analysts

Wall Street analysts see potential in the digital healthcare platform despite recent stock price declines.

Apr. 20, 2026 at 8:09am by

Got story updates? Submit your updates here. ›

An extreme close-up of the intricate machinery and cabling inside a financial data center, representing the complex infrastructure that powers modern banking and finance.Doximity's digital healthcare platform relies on robust backend technology to securely connect clinicians and deliver critical medical information.San Francisco Today

Shares of Doximity, Inc. (NYSE:DOCS) have received a 'Moderate Buy' consensus rating from 22 analysts covering the company, according to MarketBeat. The average 12-month price target is $41.26, suggesting potential upside from the current trading price around $24.72. While one analyst has a 'Sell' recommendation, the majority of analysts are either 'Buy' (13) or 'Strong Buy' (2) on the stock.

Why it matters

Doximity operates a digital platform for healthcare professionals, providing tools for clinical communication, telehealth, and accessing medical information. As the company navigates a challenging market environment, Wall Street's mixed but generally positive outlook suggests analysts see long-term potential in Doximity's offerings, even as the stock has declined from its 52-week high.

The details

Several analysts have adjusted their price targets and ratings on Doximity in recent months. JPMorgan Chase decreased its price target from $40 to $33, while maintaining a 'Neutral' rating. Morgan Stanley also lowered its price target from $65 to $49, but kept an 'Overweight' recommendation. On the other hand, Raymond James reiterated a 'Strong Buy' rating on the stock.

  • Doximity reported Q4 2025 earnings on February 5, 2026.
  • Insider Siddharth Sitaram sold 2,427 shares on April 10, 2026.

The players

Doximity, Inc.

A digital healthcare platform that connects physicians, nurse practitioners, and other clinicians, providing tools for communication, telehealth, and accessing medical information.

JPMorgan Chase & Co.

A global financial services firm that provides investment banking, asset management, and commercial banking services.

Morgan Stanley

A multinational investment bank and financial services company.

Raymond James Financial

A diversified financial services company providing private client group services, capital markets, asset management, banking, and other services.

Siddharth Sitaram

An insider at Doximity who sold 2,427 shares of the company's stock.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, Grocery employee

What’s next

Doximity's board has authorized a $500 million stock repurchase program, which could signal the company believes its shares are undervalued at current levels.

The takeaway

Despite recent stock price declines, Wall Street analysts see potential in Doximity's digital healthcare platform and tools, with a majority rating the stock a 'Buy' or 'Strong Buy'. However, the mixed outlook suggests the company still faces challenges as it navigates a competitive market.